^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P76.11 - Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC
Published date:
01/12/2021
Excerpt:
Advanced NSCLC patients harboring EGFR sensitive mutations (19DEL/L858R) after resistant to EGFR-TKIs and received anti-PD1/PD-L1 based treatment any lines were retrospectively analyzed...EGFR mutated NSCLC patients with short PFS to EGFR-TKIs conferred better response to following anti-PD-1/PD-L1 based immunotherapy.
